We first successfully constructed PDOs derived from tumor tissues of CRC patients in vitro and conducted a drug screening assay to find that ML264, a KLF5 inhibitor [14], could restore oxaliplatin sensitivity in CRC PDOs. The gene discussed is KLF5; the disease is neoplasm.